SILVER SPRING
Tecentriq cleared for adjuvant bladder cancer with ctDNA guidance
- Sponsor
- Genentech $RHHBY
- Drug
- Tecentriq · atezolizumab
- Indication
- muscle-invasive bladder cancer
FDA approved Genentech's Tecentriq for adjuvant treatment of muscle-invasive bladder cancer using ctDNA-guided therapy.
What this means
Tecentriq is an immunotherapy drug that boosts the immune system by blocking a protein that helps cancer cells hide. The FDA approved Tecentriq for use after surgery in muscle-invasive bladder cancer patients whose tumors show signs of lingering cancer DNA in their blood. This decision could help doctors identify which patients may benefit most from the drug and potentially reduce the risk of cancer returning.
Drug Watch — recent news on Tecentriq
- Atezolizumab Plus Gemcitabine/Cisplatin in Metastatic Urothelial Cancer - Oncodaily
- IMpower030: Atezolizumab Misses Primary Endpoint in NSCLC - Medscape
- Perioperative Atezolizumab Plus Chemotherapy Improves Outcomes in Resectable Stage II–IIIB NSCLC - The ASCO Post
- Perioperative Atezolizumab Plus Chemotherapy Extends EFS in Resectable NSCLC - onclive.com
- Perioperative atezolizumab + chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC - Medical Xpress
Sponsor Watch — recent news on Genentech
- What does the EU have that the U.S. does not?
- CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
- Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
- Roche agrees to $1bn deal with Dualitas for bispecific antibody research
- BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?